Drug Trial Radar · NCT06800157
Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Feb 27, 2023
Primary completion
May 26, 2024
Study completion Aug 30, 2024
Sponsor
- Lead sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase IIa study is designed to evaluate the dose-response relationship, efficacy, safety, and tolerability of LW402 tablets administered for 12 weeks in adult patients with active rheumatoid arthritis receiving background methotrexate (MTX) therapy.
Conditions
- Arthritis, Rheumatoid
Interventions
Drug: LW402Drug
Oral tablets administered BID
Other: placeboDrug
Placebo to match LW402 administered BID
MTXDrug
Background treatment with MTX once a week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in DAS28-CRP at Week 12Time frame: 12 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.